Enanta Pharmaceuticals to Participate in September Investor Conferences

WATERTOWN, Mass.--(BUSINESS WIRE)--Sep. 1, 2026--Enanta Pharmaceuticals, Inc.(NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in two investor conferencesin September:

• Baird 2026 Global Healthcare Conference: Fireside Chat onTuesday, September 15, 2026at1:25 p.m. ET

• H.C. Wainwright28thAnnualGlobal Investment Conference: Fireside Chat onWednesday, September 16, 2026at8:00 a.m. ET

A live webcast of each event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website atwww.enanta.com. A replay of the webcasts will be available following the presentation and will be archived for at least 30 days.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for viral infections and immunological diseases. In virology, Enanta’s clinical programs are focused on the development of first-in-disease and best-in-disease treatments for respiratory syncytial virus (RSV). The Company’s immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, with KIT, STAT6 and MRGPRX2 inhibition.

Glecaprevir, a protease inhibitor discovered by Enanta, is part of the only treatment approved for curing both acute and chronic hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET®(U.S.) and MAVIRET®(ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visitwww.enanta.comfor more information.

View source version on businesswire.com:https://www.businesswire.com/news/home/20260901786929/en/

Source: Enanta Pharmaceuticals, Inc.

• Print PagePrint Page

• Email AlertsEmail Alerts

• RSS FeedsRSS Feeds

• Contact IRContact IR